SLE preg delivery hospitalizations (77560) was associated with increased risk of CV complications, including preeclampsi

Tweet Author

Tweet Content

SLE preg delivery hospitalizations (77560) was associated with increased risk of CV complications, including preeclampsia [aOR 2.12] , peripartum cardiomyopathy (4.42), CHF (4), arrhythmias (2.2), AKI (7.7), stroke (4.8), VTE (6.9) w/ incr hosp costs https://t.co/PF6P8oDWZB https://t.co/jA2pHcciB1

Links

https://bit.ly/3Y80tSS

9 December 2022

Biosimilar Bonanza in 2023 (12.9.2022)

Dr. Jack Cush reviews more than a dozen news and journal articles from this past week on RheumNow.com.

Lupus, Sex and STDs

Biosimilar Bonanza in 2023 (12.9.2022)

Xeljanz Cancer Risks Detailed The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote n

Tweet Author

RheumNow

Tweet Content

Xeljanz Cancer Risks Detailed The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study. https://t.co/OG2OkD5Tcw https://t.co/1dZcJ5jDUj

Links

https://bit.ly/3HhSflr

Bimekizumab Efficacy in TNF-Refractory PsA Bimekizumab, a selective inhibitor of IL-17F and IL-17, has shown superior e

Tweet Author

RheumNow

Tweet Content

Bimekizumab Efficacy in TNF-Refractory PsA Bimekizumab, a selective inhibitor of IL-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active PsA who previously failed therapy with TNFi inhibitors. https://t.co/NCJvhmisNe https://t.co/Tk2d7ILHl2

Links

https://bit.ly/3FzP47m

8 December 2022

Telemedicine Updates

Several recent articles inform us of recent trends in Telemedicine.

From 1055 new polyarthralgia presentations, 88 (8.3%) Dx w/ psoriatic arthritis. PsA Dx assoc w/ a +FamHx ( OR 4.14), ps

Tweet Author

RheumNow

Tweet Content

From 1055 new polyarthralgia presentations, 88 (8.3%) Dx w/ psoriatic arthritis. PsA Dx assoc w/ a +FamHx ( OR 4.14), psoriasis (OR=78.94), erosions (OR=5.74), US +power Doppler (OR=7.11). Neg assoc w/ +RF (OR 0.03), +CCP (OR 0.06). https://t.co/YXcqUq9JCi https://t.co/PLuU6cTDab

Links

https://bit.ly/3Y7X1YF

3388 pts in J Hopkins Scleroderma study found 29% w/ calcinosis (13.5% these w/ heavy burden calcinosis/HBC). Calcinosis

Tweet Author

RheumNow

Tweet Content

3388 pts in J Hopkins Scleroderma study found 29% w/ calcinosis (13.5% these w/ heavy burden calcinosis/HBC). Calcinosis assoc w/ diffuse SSc, disease severity (PH, ILD, CVD, GI, renal crisis, myopathy)(OR 2.9- 6.9) & PM/Scl Abs (OR 17.31) https://t.co/ksdPcH9W0O https://t.co/OvI9wytf5H

Links

https://bit.ly/3VJ3lUS

8 December 2022

ACR Urges Congress to Prioritize Medicare Pay Cuts, Prior Authorization, and Telehealth

As the legislative session comes to a close, the American College of Rheumatology (ACR) is calling on members of Congress to include the Improving Seniors’ Timely Access to Care Act (H.R. 3173/S. 3018), the Supporting Medicare Providers Act of 2022 (H.R. 8800), and telehealth protections in any year-end legislative package.

Topics

SLE preg delivery hospitalizations (77560) was associated with increased risk of CV complications, including preeclampsi

Lupus, Sex and STDs

Biosimilar Bonanza in 2023 (12.9.2022)

Xeljanz Cancer Risks Detailed The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote n

Bimekizumab Efficacy in TNF-Refractory PsA Bimekizumab, a selective inhibitor of IL-17F and IL-17, has shown superior e

From 1055 new polyarthralgia presentations, 88 (8.3%) Dx w/ psoriatic arthritis. PsA Dx assoc w/ a +FamHx ( OR 4.14), ps

3388 pts in J Hopkins Scleroderma study found 29% w/ calcinosis (13.5% these w/ heavy burden calcinosis/HBC). Calcinosis

Do you get our email newsletter?